Ganciclovir丨CAS 82410-32-0

Ganciclovir丨CAS 82410-32-0 is a synthetic nucleoside analog of 2′-deoxyguanosine, classified as an antiviral drug. It is primarily used to treat and prevent infections caused by cytomegalovirus (CMV), particularly in immunocompromised patients, such as those with AIDS, organ transplant recipients, or cancer patients undergoing chemotherapy. Ganciclovir was developed to target viral DNA replication, and its specificity for viral-infected cells makes it a vital component in modern antiviral therapy.

1. Treatment of Cytomegalovirus (CMV) Infections
The most critical application of ganciclovir is in the management of CMV, a herpesvirus that can cause severe disease in people with weakened immune systems.
● CMV retinitis: In patients with AIDS, ganciclovir is commonly used to treat CMV-induced inflammation of the retina, which can lead to blindness if untreated.
● Systemic CMV infections: Used for pneumonitis, esophagitis, and colitis in transplant recipients and other high-risk groups.
● Congenital CMV: Investigational and sometimes off-label use includes treatment in neonates with congenital CMV infections, particularly to prevent or reduce hearing loss and developmental delay.
2. Prophylaxis in Organ Transplantation
Ganciclovir丨CAS 82410-32-0 is widely used as a prophylactic agent to prevent CMV infection or reactivation in solid organ and bone marrow transplant recipients.
● Preemptive therapy: In high-risk patients (e.g., CMV-positive donor to CMV-negative recipient), ganciclovir helps reduce the risk of CMV disease, which can otherwise compromise graft survival and patient health.
● Long-term immunosuppression: It is part of preventive regimens for patients on chronic immunosuppressive therapy post-transplant.
3. Treatment of Other Herpesviruses
Though less common, ganciclovir also shows activity against other herpesviruses, including:
● Herpes simplex virus (HSV) types 1 and 2
● Varicella-zoster virus (VZV)
● Epstein-Barr virus (EBV)
● Human herpesvirus-6 (HHV-6)
These applications are generally reserved for resistant cases or co-infections, especially when standard therapies (e.g., acyclovir) are ineffective.
4. Ophthalmic Use – CMV Retinitis Implant
A ganciclovir intraocular implant has been developed to provide localized, sustained release of the drug directly to the eye, particularly beneficial for CMV retinitis.
● Long-term management: Provides targeted treatment while reducing systemic exposure and side effects.
● Vision preservation: Helps maintain vision in patients at risk of blindness due to retinal involvement.
5. Oncology and Experimental Antiviral Research
Ganciclovir丨CAS 82410-32-0 is also used in experimental gene therapy and oncology research, where it functions in combination with viral or suicide gene vectors.
● Suicide gene therapy: In some experimental cancer treatments, ganciclovir is used with the HSV-tk (thymidine kinase) gene, selectively killing cancer cells that express this gene.
● Investigational antivirals: Studied for broader antiviral applications and for use in combination therapies targeting viral latency or resistance.

1. High Specificity for Virus-Infected Cells
Ganciclovir丨CAS 82410-32-0 is selectively phosphorylated by a viral enzyme (UL97 kinase) in CMV-infected cells, which leads to targeted inhibition of viral DNA polymerase without broadly affecting healthy cells.
● Reduced collateral toxicity: Compared to earlier antivirals, it offers a more targeted mechanism.
● Effective viral suppression: Reduces viral replication and spread in immunocompromised patients.
2. Established Efficacy in High-Risk Populations
Its proven clinical success in managing life-threatening infections in AIDS patients and transplant recipients makes it a cornerstone therapy.
● Life-saving role: Helps prevent vision loss, systemic infection, and graft failure.
● Versatile delivery: Available in multiple forms-oral, intravenous, and intraocular-for various clinical scenarios.
3. Role in Preventive Medicine
Ganciclovir's use in prophylaxis represents a major advancement in the prevention of opportunistic viral infections, which are a significant cause of morbidity in transplant medicine.
● Reduces hospitalization: Decreases the risk of CMV-related complications.
● Improves transplant outcomes: Contributes to long-term graft and patient survival.
4. Foundation for Newer Antivirals
Ganciclovir has paved the way for newer analogs, such as valganciclovir, which has improved oral bioavailability. However, ganciclovir remains a critical reference compound and is often used when high-dose intravenous therapy is needed.
● Cost-effective alternative: Especially in settings where newer drugs are not available or affordable.
● Established protocols: Well-documented dosage regimens, adverse effects, and monitoring procedures.

Conclusion
Ganciclovir丨CAS 82410-32-0 is a potent antiviral agent with critical applications in the treatment and prevention of CMV infections, particularly in immunocompromised individuals such as HIV/AIDS patients and transplant recipients. Its ability to target viral DNA replication with high specificity offers therapeutic benefit in both acute treatment and long-term prophylaxis. With additional applications in ophthalmology, oncology research, and herpesvirus management, ganciclovir continues to be an essential tool in modern antiviral therapy and clinical virology.